Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis

Izanne Roos, Stella Hughes, Gavin McDonnell, Charles B Malpas, Sifat Sharmin, Cavit Boz, Raed Alroughani, Serkan Ozakbas, Katherine Buzzard, Olga Skibina, Anneke van der Walt, Helmut Butzkueven, J. G. Scott, Jens Kuhle, Murat Terzi, Guy Laureys, Liesbeth Van Hijfte, Nevin John, Pierre Grammond, Francois Grand'MaisonAysun Soysal, Ana Voldsgaard Jensen, Peter Vestergaard Rasmussen, Kristina Bacher Svendsen, Ismael Barzinji, Helle Hvilsted Nielsen, Tobias Sejbæk, Sivagini Prakash, Morten Leif Munding Stilund, Arkadiusz Weglewski, Nadia Mubder Issa, Matthias Kant, Finn Thorup Sellebjerg, Orla Gray, M. Magyari, Tomas Kalincik, MSBase Study GroupDanish MS Registry Study Group

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

16 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis'. Together they form a unique fingerprint.

Neuroscience

Keyphrases